IL2 and autoimmune disease: Regarding the role of Tregs, if the aim is to inhibit them in chronic infections or tumors, vice versa the therapeutic goal is the induction or activation of Tregs in autoimmune diseases by various approaches, namely, the transfer of autologous in vitro-expanded Tregs to suppress autoimmune responses (101), or induction of Tregs directly in vivo by administration of immunocomplexes of IL-2 and specific anti-IL2 antibody selectively promoting the expansion of Tregs (expressing the high-affinity trimeric IL-2R that includes IL-2Rα) without expanding activated effector T cells (102, 103).